Novartis

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

Retrieved on: 
Friday, February 9, 2024

BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.

Key Points: 
  • BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
  • Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.
  • Trastuzumab is a biosimilar of Herceptin® and Bevacizumab is a biosimilar of Avastin®3 – both biosimilars are available on the PBS and utilised for the treatment of various cancers.
  • OGIVRI® and ABEVMY® are registered trademarks of Biosimilars Newco Limited, a Biocon Biologics Company.

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Retrieved on: 
Thursday, February 8, 2024

WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately.

Key Points: 
  • WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately.
  • Ms. Landon is an accomplished commercial leader with over 26 years’ experience launching, building, and transforming commercial teams and brands in the pharmaceutical industry.
  • “We screened hundreds of applicants during the second half of 2023 and Kristen’s vision and directly relevant experience made her the ideal match for the position,” said Geoff Dow, PhD., 60 Degrees Pharma Chief Executive Officer.
  • Ms. Landon holds an MBA from Silberman College of Business at Fairleigh Dickinson University, and a Bachelor’s degree from Kean University.

PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development

Retrieved on: 
Thursday, February 8, 2024

LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.

Key Points: 
  • LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.
  • "With his extensive experience in healthcare and specifically molecular diagnostics, I am pleased to welcome Chris to PreludeDx's leadership team.
  • Chris brings more than 25 years of experience in healthcare across laboratory services, medical device and biopharmaceutical companies, with senior leadership roles in marketing, sales and business development in the cancer diagnostics market.
  • He joins PreludeDx from HALO Precision Diagnostics where he served as the Chief Business Officer – Molecular Diagnostics.

EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Key Points: 
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    The issuer is solely responsible for the content of this announcement.
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality.
  • Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
  • If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
    Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Key Points: 
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality.
  • Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
  • Marc de Garidel, Chief Executive Officer of Abivax, says: “I am glad Ana joins our team with her extensive experience in research and development quality assurance in the biopharmaceutical sector.
  • If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
    Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.

Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors

Retrieved on: 
Tuesday, February 6, 2024

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.
  • "The field of animal health is hungry for innovative solutions to address our pets' health concerns,” said Aaron Schacht.
  • Mr. Schacht led several strategic acquisitions, including Bayer Animal Health, Aratana Therapeutics, and Kindred Biosciences.
  • Additionally, he integrated R&D capabilities and pipelines from Novartis Animal Health, Boehringer Ingelheim pet vaccines, Bayer Animal Health, Aratana, Prevtec, and Kindred.

PRIME® Study on Real-World Disparities in LGBTQ+ Cancer Care Wins Prestigious William Campbell Felch Award

Retrieved on: 
Tuesday, February 6, 2024

This marks the third time PRIME has won the award in the last five years.

Key Points: 
  • This marks the third time PRIME has won the award in the last five years.
  • PRIME’s research-driven initiative was designed to identify and address real-world disparities in LGBTQ+ cancer care and drive sustainable change in practice across oncology care settings.
  • This landmark initiative demonstrates how utilizing real-world patient insights and research-driven education can be a sustainable catalyst for advancing equitable cancer care.
  • We are honored that this important work has been recognized through the prestigious Felch award," says Chris Napolitan, Managing Director of PRIME.

EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Retrieved on: 
Tuesday, February 6, 2024

Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).

Key Points: 
  • Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).
  • “Novartis shares our steadfast commitment to develop and deliver transformative medicines that address the dire needs of cancer patients.
  • Novartis intends to offer MorphoSys’ shareholders € 68.00 per share in cash, for a total equity value of € 2.7 billion.
  • Creates New Opportunities for MorphoSys’ Colleagues: The agreement between Novartis and MorphoSys includes employee commitments.

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Retrieved on: 
Monday, February 5, 2024

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Key Points: 
  • NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
    BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today.
  • With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader.
  • Earlier in his career, Thomas served in key leadership roles in clinical and medical assessment, business development and market access at Novartis.
  • Alan Watt, Chief Executive Officer of NodThera, said: “We are delighted to welcome Thomas to the NodThera team, with his wealth of sector experience and successful execution of drug development programs across multiple therapeutic areas.

Mondelēz International Appoints Brian McNamara to Board of Directors

Retrieved on: 
Friday, February 2, 2024

CHICAGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) today announced the appointment of Brian McNamara to the Company’s Board of Directors, effective Feb. 1.

Key Points: 
  • CHICAGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) today announced the appointment of Brian McNamara to the Company’s Board of Directors, effective Feb. 1.
  • McNamara has served as Chief Executive Officer of Haleon plc, formerly GSK Consumer Healthcare, since May 2022.
  • He currently sits on Haleon’s Board of Directors, as well as the Board of Directors of the Consumer Goods Forum.
  • McNamara’s appointment expands the size of the Company’s Board to 11 members, 10 of whom are deemed independent, including McNamara.